FDA gene therapy office director
Executive Summary
Center for Biologics Evaluation & Research's Office of Cellular, Tissue & Gene Therapies' new director is Celia Witten. She was previously head of the Center for Devices & Radiological Health's Division of General, Restorative & Neurological Devices. The gene therapy office had been headed by former Intronn COO Edward Otto, who joined in November (1"The Pink Sheet" Nov. 1, 2004, In Brief). Otto left "to pursue outside interests," the agency said. Witten assumed her new role March 7...
You may also be interested in...
CBER cell therapies office director
FDA names former Intronn COO Edward Otto, PhD, director of the Center for Biologics Evaluation & Research Office of Cellular, Tissue & Gene Therapies, effective Nov. 14. Deputy Director Joyce Frey-Vasconcells, PhD, has served as acting director of CBER's cell therapies office since May after Acting Director Phil Noguchi, MD, moved temporarily to the Office of Orphan Products Development. Noguchi left FDA at the end of August to join Amgen (1"The Pink Sheet" Sept. 27, 2004, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.